Dysbiosis and primary B-cell immunodeficiencies: current knowledge and future perspective.

Area of Science:

• Immunology
• Microbiology
• Gastroenterology

Background:

• The human gut microbiota, comprising trillions of symbiotic microbes, significantly influences immune homeostasis both locally and systemically.
• Primary B-cell immunodeficiencies (PBIDs) are characterized by impaired antibody production due to genetic defects or B-cell dysfunction.
• PBIDs are increasingly linked to disruptions in gut homeostasis, leading to dysbiosis and compromised gastrointestinal immune surveillance.

Purpose of the Study:

• To comprehensively review existing literature on the interplay between the gut microbiome and Primary B-cell immunodeficiencies (PBIDs).
• To elucidate factors influencing gut microbiota composition in individuals with PBIDs.
• To explore potential therapeutic strategies for modulating the gut microbiome in PBID management.

Main Methods:

• Systematic review of published research articles.
• Analysis of studies investigating gut microbiome alterations in PBID patients.
• Synthesis of data on factors affecting gut microbiota and potential clinical interventions.

Main Results:

• PBIDs are associated with significant alterations in gut microbial composition and function.
• Specific factors contributing to dysbiosis in PBID patients have been identified.
• Emerging evidence suggests therapeutic potential for microbiome-targeted interventions.

Conclusions:

• The gut microbiome plays a critical role in the pathogenesis and immune dysregulation observed in PBIDs.
• Understanding the gut microbiome-PBID axis is crucial for developing novel diagnostic and therapeutic approaches.
• Restoring microbial balance holds promise for improving immune function and clinical outcomes in PBID patients.